The high therapeutic efficacy of IL-17-, TNF-α-, and IL-23-targeting biologics for treating psoriasis supports the central role of IL-17-producing T-cells in the development of psoriatic inflammation31. The gene discussed is IL17A; the disease is psoriasis.